Updated safety and efficacy of MSB2311 (an anti-programmed death-ligand 1 antibody) in Chinese patients with advanced solid tumors and hematological malignancies from a phase 1 study.

doi:10.1200/JCO.2021.39.15_suppl.e14547

	Updated safety and efficacy of MSB2311 (an anti-programmed death-ligand 1 antibody) in Chinese patients with advanced solid tumors and hematological malignancies from a phase 1 study.
	Shen, Lin ; Gong, Jifang ; Zhang, Jian ; Ji, Dongmei ; Zhong, Haijun ; Yuan, Ying ; Yang, Lei ; Zhang, Qingyuan ; Li, Yufeng ; Wang, Mengde
刊名	JOURNAL OF CLINICAL ONCOLOGY
	2021-05-20
卷号	39
ISSN号	0732-183X
DOI	10.1200/JCO.2021.39.15_suppl.e14547
资助项目	Mabspace Biosciences (Suzhou) Co., Limited, Suzhou, China
WOS研究方向	Oncology
语种	英语
出版者	LIPPINCOTT WILLIAMS & WILKINS
WOS记录号	WOS:000708120301043
资助机构	Mabspace Biosciences (Suzhou) Co., Limited, Suzhou, China
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/126478]
专题	中国科学院合肥物质科学研究院
作者单位	1.Zhejiang Univ, Sch Med, Affiliated Hosp 2, Hangzhou, Peoples R China 2.Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China 3.Fudan Univ, Dept Med Oncol, Canc Hosp, Shanghai, Peoples R China 4.Mabspace Biosci Suzhou Co Ltd, Suzhou, NJ, Peoples R China 5.Mabspace Biosci Co Ltd, Suzhou, NJ, Peoples R China 6.Harbin Med Univ Canc Hosp, Harbin, Peoples R China 7.Nantong Canc Hosp, Nantong, Peoples R China 8.Univ Chinese Acad Sci, Canc Hosp, Chinese Acad Sci,Dept Med Oncol, Zhejiang Canc Hosp,Inst Canc & Basic Med, Hangzhou, Peoples R China 9.Fudan Univ, Shanghai Canc Ctr, Dept Med Oncol, Shanghai, Peoples R China 10.Peking Univ, Sch Oncol, Beijing, Peoples R China
推荐引用方式 GB/T 7714	Shen, Lin,Gong, Jifang,Zhang, Jian,et al. Updated safety and efficacy of MSB2311 (an anti-programmed death-ligand 1 antibody) in Chinese patients with advanced solid tumors and hematological malignancies from a phase 1 study.[J]. JOURNAL OF CLINICAL ONCOLOGY,2021,39.
APA	Shen, Lin.,Gong, Jifang.,Zhang, Jian.,Ji, Dongmei.,Zhong, Haijun.,...&Hu, Xichun.(2021).Updated safety and efficacy of MSB2311 (an anti-programmed death-ligand 1 antibody) in Chinese patients with advanced solid tumors and hematological malignancies from a phase 1 study..JOURNAL OF CLINICAL ONCOLOGY,39.
MLA	Shen, Lin,et al."Updated safety and efficacy of MSB2311 (an anti-programmed death-ligand 1 antibody) in Chinese patients with advanced solid tumors and hematological malignancies from a phase 1 study.".JOURNAL OF CLINICAL ONCOLOGY 39(2021).